Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) February 2, 2007

 

Cell Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Washington   001-12465   91-1533912

(State or other jurisdiction

of incorporation)

   (Commission File No.)  

(I.R.S. Employer

Identification No.)

501 Elliott Avenue West, Suite 400

Seattle, Washington 98119

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: 206-282-7100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant

under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 3.03 Material Modification to Rights of Security Holders.

On February 2, 2007, the Company filed an amendment to its Articles of Incorporation establishing a one-for-four reverse stock spit, effective at the close of business Pacific Time on April 2, 2007.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On February 2, 2007, the Company filed an amendment to its Articles of Incorporation establishing a one-for-four reverse stock spit, effective at the close of business Pacific Time on Aprile 2, 2007.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. The following exhibits are included in this report:

 

  99.1 Amendment to Articles of Incorporation..

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  CELL THERAPEUTICS, INC.
Date: February 2, 2007   By:  

/s/ Louis A. Bianco

    Louis A. Bianco
    Executive Vice President, Finance and Administration